Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia
Portfolio Pulse from
Tonix Pharmaceuticals has announced that the FDA has set a PDUFA goal date of August 15, 2025, for the decision on the U.S. marketing approval of TNX-102 SL, a treatment for fibromyalgia.
December 23, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals has been granted a PDUFA goal date by the FDA for its drug TNX-102 SL, aimed at treating fibromyalgia. The decision is expected by August 15, 2025.
The announcement of a PDUFA date is a significant milestone for Tonix Pharmaceuticals as it indicates progress towards potential FDA approval. This news is likely to positively impact TNXP's stock price in the short term as it reflects advancement in their drug development pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100